- Trials with a EudraCT protocol (44,359)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,359 result(s) found.
Displaying page 1,933 of 2,218.
EudraCT Number: 2007-002352-41 | Sponsor Protocol Number: HDL07-01 | Start Date*: 2007-08-21 | ||||||||||||||||
Sponsor Name:Helsingin Diakonissalaitos | ||||||||||||||||||
Full Title: Lyhyt ja pitkä buprenorfiini-naloksoni -hoito suonensisäisen buprenorfiiniriippuvuuden vieroitushoidossa. Satunnaistettu kontrolloitu tutkimus | ||||||||||||||||||
Medical condition: Opiaattiriippuvuus, buprenorfiinin suonensisäinen väärinkäyttö | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003845-36 | Sponsor Protocol Number: EFTISARC-NEO/NIO-0004 | Start Date*: 2023-04-13 | |||||||||||
Sponsor Name:Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy | |||||||||||||
Full Title: A Phase II, single-arm clinical trial evaluating efficacy and safety of pembrolizumab in combination with a soluble LAG-3 protein, eftilagimod alpha, and radiotherapy in neoadjuvant treatment of pa... | |||||||||||||
Medical condition: Resectable soft tissue sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-006143-26 | Sponsor Protocol Number: 2019/ABM/01/00062 | Start Date*: 2021-05-02 | |||||||||||
Sponsor Name:Śląski Uniwersytet Medyczny w Katowicach | |||||||||||||
Full Title: A Single center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of neoadjuvant and adjuvant Pembrolizumab on top of standard Chemo-Radiotherapy (Stupp protocol) in Treatment of Pa... | |||||||||||||
Medical condition: Glioblastoma Multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002171-11 | Sponsor Protocol Number: 010622 | Start Date*: 2024-07-02 |
Sponsor Name:Medical University of Łódź | ||
Full Title: Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic functional connectivity, cognitive functions, quality of ... | ||
Medical condition: dementia and mild cognitice impairment due to Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002630-17 | Sponsor Protocol Number: NBK132/2/2021 | Start Date*: 2022-02-02 |
Sponsor Name:Medical Unicersity of Gdansk | ||
Full Title: Treatment of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and Dexamethasone (BGD) with autologous bone marrow transplantation in lymphoma patients Hodgkin resistant to treatmen... | ||
Medical condition: Refractory / relapsed Hodgkin's lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004454-17 | Sponsor Protocol Number: ACE-CL-309 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:Acerta Pharma BV | |||||||||||||
Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Rela... | |||||||||||||
Medical condition: Relapsed or Refractory Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Trial now transitioned) SK (Completed) SE (Completed) ES (Ongoing) CZ (Trial now transitioned) AT (Completed) DE (Completed) FR (Completed) BG (Completed) PL (Trial now transitioned) HR (Trial now transitioned) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004877-38 | Sponsor Protocol Number: PREVENT-MINS | Start Date*: 2021-06-18 | |||||||||||
Sponsor Name:Uniwersytet Jagielloński - Collegium Medicum | |||||||||||||
Full Title: Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial | |||||||||||||
Medical condition: Myocardial Injury after Noncardiac Surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000036-30 | Sponsor Protocol Number: NBK151/1/2022 | Start Date*: 2023-08-31 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma. | ||
Medical condition: Hepatoblastoma and liver cancer (hepatocarcinoma) | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004982-37 | Sponsor Protocol Number: NBK155/1/2020 | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:MEDICAL UNIVERSITY OF GDAŃSK | |||||||||||||
Full Title: Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome | |||||||||||||
Medical condition: NEPHROTIC SYNDROME | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004962-21 | Sponsor Protocol Number: MC-ACS01-2020 | Start Date*: 2021-07-18 | ||||||||||||||||||||||||||
Sponsor Name:Wojskowy Instytut Medyczny | ||||||||||||||||||||||||||||
Full Title: "MetCool ACS”- Metformin “Cooling” Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome | ||||||||||||||||||||||||||||
Medical condition: Acute coronary syndrome | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001555-14 | Sponsor Protocol Number: NBK272/1/2021 | Start Date*: 2023-01-05 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseases | ||
Medical condition: fibrotic interstitial lung disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003625-16 | Sponsor Protocol Number: TG1101-RMS303 | Start Date*: 2020-04-15 | |||||||||||
Sponsor Name:TG Therapeutics, Inc. | |||||||||||||
Full Title: An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001522-25 | Sponsor Protocol Number: CLCI699C2203 | Start Date*: 2019-03-19 | |||||||||||
Sponsor Name:Recordati AG | |||||||||||||
Full Title: A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s di... | |||||||||||||
Medical condition: Cushing's disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SI (Completed) BG (Completed) BE (Trial now transitioned) ES (Prematurely Ended) IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001314-24 | Sponsor Protocol Number: 111JC101 | Start Date*: 2009-01-02 | |||||||||||
Sponsor Name:Biogen Idec Ltd | |||||||||||||
Full Title: A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | |||||||||||||
Medical condition: Progressive Multifocal Leukoencephalopathy (PML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005288-31 | Sponsor Protocol Number: MORF-057-201 | Start Date*: 2022-07-04 | |||||||||||
Sponsor Name:Morphic Therapeutic, Inc. | |||||||||||||
Full Title: A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis | |||||||||||||
Medical condition: Moderate to Severe Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000513-14 | Sponsor Protocol Number: NBK154/2/2021 | Start Date*: 2023-03-08 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan-type Heritable Thoracic Aortic Diseases – Valsar-TAD, a randomised, double-b... | ||
Medical condition: Marfan Syndrome Diseases related to Marfan syndrome (rare diseases with aneurysms of the thoracic aorta and dissection of the aorta), among others: Loeys-Dietz syndrome, Vascular type of Ehlers-Da... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005648-52 | Sponsor Protocol Number: D1346C00015 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase I, Single-Arm, Sequential Study to Evaluate the Effect of Food on the Gastrointestinal Tolerability and Pharmacokinetics of Selumetinib after Multiple Doses in Adolescent Children with Neur... | |||||||||||||
Medical condition: Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002977-37 | Sponsor Protocol Number: CRAD001M2X02B | Start Date*: 2017-08-25 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued t... | |||||||||||||
Medical condition: Refractory seizures associated with tuberous sclerosis complex | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) BE (Completed) FR (Completed) PL (Trial now transitioned) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005019-29 | Sponsor Protocol Number: Rux-cALL-Pol_2020 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Medical University of Lodz | ||||||||||||||||||
Full Title: Single-arm interventional study with ruxolitinib and AIOEP-BFM2017 chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. | ||||||||||||||||||
Medical condition: Acute Lymphoblastic Leukemia with confirmed activating of JAK/STAT pathway in children and adolescents <18 years of age | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005740-27 | Sponsor Protocol Number: 2019/ABM/01/00081 | Start Date*: 2021-04-19 | |||||||||||
Sponsor Name:Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu | |||||||||||||
Full Title: Effect of Intravenous FERRic carboxymaltose on mortality and cardiovascular morbidity, and quality of life in iron deficient patients with recent myocardial infarction | |||||||||||||
Medical condition: Recent myocardial infarction associated with iron deficient | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
